These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11266084)

  • 1. DNA tumor vaccines.
    Wlazlo AP; Ertl HC
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):1-11. PubMed ID: 11266084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccination against tumors.
    Prud'homme GJ
    J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-based vaccination against tumors expressing the P1A antigen.
    Rosato A; Milan G; Collavo D; Zanovello P
    Methods; 1999 Sep; 19(1):187-90. PubMed ID: 10525455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA gene fusion vaccines against cancer.
    Zhu D; Stevenson FK
    Curr Opin Mol Ther; 2002 Feb; 4(1):41-8. PubMed ID: 11883694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
    U'Ren L; Kedl R; Dow S
    Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N; King CA; Vitetta ES; Stevenson FK
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
    Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
    Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine gene-engineered vaccines.
    Forni G; Boggio K
    Curr Opin Mol Ther; 1999 Feb; 1(1):34-8. PubMed ID: 11249681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
    Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM
    Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
    Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
    Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifying professional antigen-presenting cells to enhance DNA vaccine potency.
    Hung CF; Yang M; Wu TC
    Methods Mol Med; 2006; 127():199-220. PubMed ID: 16988456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
    Pavlenko M; Leder C; Pisa P
    Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.